Document Classification

Section Type: RESULTS

Text: The superiority of enzalutamide over placebo was shown with respect to all secondary end points : the proportion of patients with a reduction in the prostate-specific antigen (PSA) level by 50 % or more (54 % vs. 2 %, P < 0. 001), the soft-tissue response rate (29 % vs. 4 %, P < 0. 001), the quality-of-life response rate (43 % vs. 18 %, P < 0. 001), the time to PSA progression (8. 3 vs. 3. 0 months ; hazard ratio, 0. 25 ; P < 0. 001), radiographic progression-free survival (8. 3 vs. 2. 9 months ; hazard ratio, 0. 40 ; P < 0. 001), and the time to the first skeletal-related event (16. 7 vs. 13. 3 months ; hazard ratio, 0. 69 ; P < 0. 001).